Syndax Pharmaceuticals SNDX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$243.25M+14.8% | -$285.42M+8.4% | -$311.58M+7.0% | -$334.99M-1.1% | -$331.2M-3.9% | ||
| $49.18M+3.5% | $47.5M-2.1% | $48.55M+0.3% | $48.4M+8.7% | $44.51M+3.4% | ||
| $173K-24.5% | $229K-11.6% | $259K+31.5% | $197K+38.7% | $142K+373% | ||
| $22.15M-27.1% | $30.39M+19.6% | $25.4M+30.6% | $19.45M+23.7% | $15.72M+107% | ||
| $29.96M-6.6% | $32.09M+30.2% | $24.66M+41.1% | $17.47M+283% | $4.56M+1,145% | ||
| —— | —— | —— | $5.79M+367% | $1.24M-25.6% | ||
| $16.35M-61.2% | $42.17M+49.9% | $28.13M-41.5% | $48.06M+106% | $23.32M+21.8% | ||
| $12.7M-12.7% | $14.54M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $344K-94.7% | $6.44M+3,923% | $160K— | —— | —— | ||
| -$278.16M+13.9% | -$322.98M-3.9% | -$310.88M-2.7% | -$302.67M-5.6% | -$286.52M-4.2% | ||
| $224.66M+14.7% | $195.81M-61.5% | $509.01M+3.5% | $491.92M+22.9% | $400.21M-28.2% | ||
| $459.13M-5.5% | $486.03M+8.3% | $448.62M+0.6% | $445.82M+19.2% | $373.97M+10.9% | ||
| $234.28M-19.2% | $290.04M+579% | -$60.52M-31.3% | -$46.1M— | —— | ||
| $20.66M+51.1% | $13.68M-96.1% | $355.18M+0.9% | $352M0.0% | $352.13M-0.4% | ||
| —— | —— | —— | —— | —— | ||
| $8.02M-25.5% | $10.75M-11.6% | $12.16M-5.0% | $12.81M-3.3% | $13.25M-1.6% | ||
| $173K-24.5% | $229K-11.6% | $259K+31.5% | $197K+38.7% | $142K+373% | ||
| $10K+66.7% | $6K+100% | $3K+50.0% | $2K-60.0% | $5K-37.5% | ||
| $344K-94.7% | $6.44M+3,923% | $160K— | —— | —— | ||
| $16.35M-61.2% | $42.17M+49.9% | $28.13M-41.5% | $48.06M+106% | $23.32M+21.8% | ||
| -$32.69M+23.9% | -$42.98M-102% | -$21.24M-37.8% | -$15.42M-432% | $4.64M-61.3% | ||
| $12.7M-12.7% | $14.54M— | —— | —— | —— | ||
| —— | $163K+33.3% | $122.25K+50.0% | $81.5K+100% | $40.75K— | ||
| $855K-9.6% | $946K+24.6% | $759K-15.3% | $896K-7.2% | $966K-2.3% | ||
| —— | $3.67M+33.3% | $2.75M— | —— | —— | ||
| $224.66M+14.7% | $195.81M-61.5% | $509.01M+3.5% | $491.92M+22.9% | $400.21M-28.2% | ||
| $459.13M-5.5% | $486.03M+8.3% | $448.62M+0.6% | $445.82M+19.2% | $373.97M+10.9% | ||
| —— | $0-100% | $85.91M-50.0% | $171.83M-33.3% | $257.74M-25.0% | ||
| $1.53M-5.4% | $1.62M-1.8% | $1.65M-24.5% | $2.18M+11.8% | $1.95M+13.8% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0-100% | $381K-50.0% | $762K-33.3% | $1.14M-25.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Syndax Pharmaceuticals generate?
- Syndax Pharmaceuticals (SNDX) generated -$278.2M in operating cash flow over the trailing twelve months.
- Where does Syndax Pharmaceuticals's cash flow data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
